Daiichi Sankyo says Sayonara to India; terminates contract of 170 employees

The company's closure of R&D establishment in Gurgaon marks its exit from Indian market

Japanese drug maker Daiichi Sankyo marked its exit from the Indian market with the closure of its Research and Development establishment in Gurgaon.

The company will terminate the contracts of its 170 employees. In an e-mail response to Business Standard's query, the company said, "We plan to resolve labor contracts after reaching agreements with all DSIN employees."

Employees Business Standard spoke to said that end of January would be their last working day. An employee said, "The Company is providing us with adequate compensation and there is no tussle with the management." 

Daiichi Sankyo acquired Ranbaxy's R&D businessin 2008 with